Vaccine directed to induction of immune response to protein and glycolipid antigens of bacterial cells through interaction of CD4OL/CD40 receptor axis with complex of glycolipid/CD1d receptor in NKT cells and in dendritic cells
US10383932B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Apr 26, 2016 |
| Grant date | Aug 20, 2019 |
| Priority date | — |
| Expiry date | Aug 27, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/10343
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A combination of components to promote an innate and adaptive immune response comprising of a TAA/ecdCD40L vaccine and a complex between the CD1d receptor and an alpha galactosyl ceramide like glycolipid (AGCLGL), to activate NKT cells and activate the CD40 receptor on the DCs and increase the level of the adaptive immune response induced by the TAA/ecdCD40L vaccine to the TAA. The result and advantage of using both the TAA/ecdCD40L vaccine and the α-galactosylceramide-CD1d complex (or a related bacterial or other antigen related to α-galactosylceramide) to stimulate the immune response through the CD40L/CD40 axis on dendritic cells, is that the magnitude of the stimulation is robust and increased significantly more than additive—i.e. synergistically due to the interaction, cross-talk and/or cross-stimulation of the glycolipid-CD1d pathway and TAA/ecdCD40L pathway. As a result, a potent immune response is induced against lipid target antigens as well as protein target antigens.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.